<DOC>
	<DOCNO>NCT02483416</DOCNO>
	<brief_summary>The study take place period 27 month . The recruitment phase last approximately 24 month patient participate approximately 3 month . At inclusion visit ( D0 ) , investigator ask patient whether would like participate study obtain write consent . Patients agree participate randomise ( 3:1 ratio ) include one follow 2 group : Group without ` remote additional personalise nurse-led follow-up : patient receive healthcare give routinely medical team ( 100 patient ) . Group ` remote additional personalise nurse-led follow-up : patient receive telephone call nurse addition healthcare give routinely medical team ( 300 patient ) . All patient see accord normal practice study medical team . Patients group ` remote additional personalise nurse-led follow-up contact 8 time study ( D1 , D7 , D14 , D21 , D28 , D44 , D59 D89 ) . The nurse make sure treatment take place good condition ; intervene medical care patient , give answer question relative disease treatment patient . The medical team remain privileged contact patient .</brief_summary>
	<brief_title>Evaluation Impact Nurse-led Telephone Treatment Compliance</brief_title>
	<detailed_description>Purpose : Study Design :</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Inclusion criterion : Male female patient old 18 year . Adult patient diagnose stage IIIb/IV NSCLC locally advance metastatic , activate mutation ( ) EGFR EGFRTKI na√Øve . Patient decision treatment afatinib monotherapy take frame marketing authorization . Outpatient . Patient give write consent participation study . Patient able participate investigator 's opinion . Patient affiliate French social security . Exclusion criterion : Patients participate interventional clinical study . Patients participation interventional clinical study foresee within 3 month follow study inclusion . Patients participate therapeutic education program .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>